Core Viewpoint - The article discusses the potential winners of the Nobel Prize in Physiology or Medicine, focusing on the significance of scientific discoveries and their applications in the medical field, particularly highlighting the discovery of GLP-1 as a strong candidate for the award in 2025 [1][3]. Group 1: Historical Context and Trends - The Nobel Prize in Physiology or Medicine has historically awarded discoveries that are significant in both scientific and practical applications, with a distribution ratio of approximately 3:2 between physiology and medicine since 2001 [1][2]. - The awarding pattern shows a tendency to recognize impactful medical discoveries every few years, with the last notable award in the metabolic research area occurring 40 years ago [6][7]. Group 2: GLP-1 Discovery - The discovery of GLP-1 is considered a major breakthrough in metabolic regulation, with an 85% probability of winning the Nobel Prize due to its significant scientific and practical implications [3][4]. - GLP-1-based drugs, such as semaglutide and tirzepatide, are projected to rank among the top ten global drug sales in 2024, showcasing their widespread application and importance in treating obesity [4][5]. - The recognition of GLP-1's importance has grown in recent years, and it has been a contender for major scientific awards, indicating its readiness for Nobel recognition [6][7]. Group 3: Potential Awardees - Key contributors to the discovery of GLP-1 include Jens Juul Holst and Joel Habener, both with a 100% probability of winning due to their foundational work in identifying and characterizing GLP-1 [8][10]. - Svetlana Mojsov, another significant contributor, has a 75% probability of winning, while Daniel Joshua Drucker and Lotte Knudsen have lower probabilities of 20% and 5%, respectively, due to their roles being more focused on later developments rather than the initial discovery [12][15][17]. Group 4: Other Potential Projects - Other projects, such as the development of fMRI and PET technologies, have a lower probability of winning (15%) due to their perceived lack of groundbreaking discovery elements compared to GLP-1 [19][21]. - Additional medical achievements, including Herceptin and Gleevec, are noted for their clinical significance but are considered less competitive against GLP-1 [22][23]. - Basic research achievements in physiology are deemed unlikely to win, with a probability of less than 1% due to the vast number of contributions in this area [24].

Group 1 - The use of sedatives in ICU is essential to manage patients' anxiety, tension, and fear, which can hinder treatment and increase oxygen consumption, affecting recovery success rates [2][4] - Common sedatives used in ICU include Diazepam, Midazolam, Propofol, and Dexmedetomidine, which help patients through critical phases of illness by inducing a state similar to deep sleep, with full cognitive recovery after the drug effects wear off [3][4] - The administration of sedatives is strictly controlled in terms of dosage and duration to prevent dependency, with studies indicating that long-term cognitive impairment in critically ill patients is more related to the severity of illness rather than the sedatives themselves [4] Group 2 - Opioid analgesics such as Codeine, Hydrocodone, Oxycodone, Morphine, Sufentanil, and Remifentanil are also used in ICU, providing strong pain relief but with potential for addiction, necessitating careful monitoring by healthcare professionals [3][4] - Individualized sedation strategies are implemented based on patient-specific factors like weight and organ function, ensuring comfort during treatment while safeguarding long-term cognitive health [4]

Core Viewpoint - Baili Tianheng has experienced a significant financial downturn, transitioning from a profit of 3.7 billion yuan to a loss of 530 million yuan, while simultaneously pursuing financing through a public offering [2][3]. Group 1: Financial Performance - In Q1 2025, Baili Tianheng's revenue plummeted by 99.7% to 67 million yuan, with a net loss of 531 million yuan [3]. - The company reported a net profit of 3.7 billion yuan in 2024, a dramatic increase of 580% from a loss of 780 million yuan in the previous year, primarily due to an 800 million USD upfront payment from Bristol-Myers Squibb [3]. - The revenue sources for 2024 included 5.332 billion yuan from intellectual property licensing, 322 million yuan from chemical drug formulations, and 164 million yuan from traditional Chinese medicine formulations [3]. Group 2: Financing and Capital Needs - Baili Tianheng's funding gap for the next three years is estimated at 4.819 billion yuan, indicating a significant need for capital [3]. - The company has received approval for a private placement to raise up to 3.764 billion yuan, with plans to issue no more than 20.05 million shares to specific investors [2][3]. - In addition to the A-share private placement, Baili Tianheng is also pursuing a listing on the Hong Kong Stock Exchange to enhance its international business and financing capabilities [3][4]. Group 3: Product Pipeline and Market Position - The company has secured an 8.4 billion USD collaboration agreement for its innovative drug BL-B01D1, which is a dual-target antibody-drug conjugate (ADC) aimed at treating non-small cell lung cancer and breast cancer [4]. - Baili Tianheng has 14 drug candidates in clinical trials, with 6 ADC innovative drugs, including BL-B01D1, currently in clinical stages [4]. - The company faces intense competition in the ADC market, and its ability to maintain market position may be jeopardized if it cannot secure necessary funding to expedite product launches [4].